Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.
Identification of clinically viable quinolinol inhibitors of botulinum neurotoxin A light chain.
复制标题
DOI:
10.1021/jm4012164
复制
发表时间:
2014-02-13
影响因子:
7.3
通讯作者:
Dickerson TJ
中科院分区:
文献类型:
--
作者:
Caglič D;Krutein MC;Bompiani KM;Barlow DJ;Benoni G;Pelletier JC;Reitz AB;Lairson LL;Houseknecht KL;Smith GR;Dickerson TJ
Botulinum neurotoxins (BoNT) are the most potent toxins known and a significant bioterrorist threat. Few small molecule compounds have been identified that are active in cell-based or animal models, potentially due to toxin enzyme plasticity. Here we screened commercially available quinolinols, as well as synthesized hydroxyquinolines. Seventy-two compounds had IC50 values below 10 μM, with the best compound exhibiting submicromolar inhibition (IC50 = 0.8 μM). Structure–activity relationship trends showed that the enzyme tolerates various substitutions at R1 but has a clear preference for bulky aryl amide groups at R2, while methylation at R3 increased inhibitor potency. Evaluation of the most potent compounds in an ADME panel showed that these compounds possess poor solubility at pH 6.8, but display excellent solubility at low pH, suggesting that oral dosing may be possible. Our data show the potential of quinolinol compounds as BoNT therapeutics due to their good in vitro potencies and favorable ADME properties.
登录
查看更多内容
影响因子:
5
作者:
Capek, Petr;Zhang, Yan;Dickerson, Tobin J.
通讯作者:
Dickerson, Tobin J.
影响因子:
2.7
作者:
Smith, Garry R.;Caglic, Dejan;Dickerson, Tobin J.
通讯作者:
Dickerson, Tobin J.
影响因子:
4.9
作者:
Boldt, Grant E.;Eubanks, Lisa M.;Janda, Kim D.
通讯作者:
Janda, Kim D.
影响因子:
3.5
作者:
Burnett, JC;Schmidt, JJ;Bavari, S
通讯作者:
Bavari, S
影响因子:
1.2
作者:
Caglic, Dejan;Bompiani, Kristin M.;Dickerson, Tobin J.
通讯作者:
Dickerson, Tobin J.